Novartis: Anemia, Sickle Cell trials

The registry lists 25 Anemia, Sickle Cell studies with Novartis as lead sponsor. 4 are open to participants now and 10 have results posted.

Phase 1 3Phase 2 9Phase 3 3Phase 4 2No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell DiseaseRecruitingNCT06546670Phase 1/2
• A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)RecruitingNCT06439082Phase 3
• Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab StudyRecruitingNCT04657822Phase 4
• Managed Access Programs for SEG101, CrizanlizumabAvailableNCT03720626
• An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease PatientsCompletedNCT04662931Phase 4Results posted
• Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell DiseaseCompletedNCT04053764Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related PriapismCompletedNCT03938454Phase 2Results posted
• Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease PatientsActive, not recruitingNCT03814746Phase 3Results posted
• Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease PatientsCompletedNCT03474965Phase 2Results posted
• Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)CompletedNCT03264989Phase 2Results posted
• Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell AnemiaCompletedNCT02961218Phase 2Results posted
• Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).CompletedNCT01090323Phase 2Results posted
• Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadCompletedNCT00235391Phase 3Results posted
• Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease PatientsCompletedNCT00110617Phase 2Results posted
• Crizanlizumab Pregnancy Outcomes Intensive MonitoringCompletedNCT07554547
• Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell CentersCompletedNCT06662825
• Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery RegistryCompletedNCT06662812
• Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)Active, not recruitingNCT06155500Phase 1
• Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell CentersCompletedNCT05833022
• Characteristics of Patients With Sickle Cell DiseaseCompletedNCT05494541
• Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and IndiaTerminatedNCT05020873
• Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)TerminatedNCT04443907Phase 1
• Sickle Cell Disease: A Retrospective Chart ReviewCompletedNCT01441375
• A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) PatientsCompletedNCT01220115
• Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood TransfusionsCompletedNCT00067080Phase 2